Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of SEP-363856 versus placebo in adults with generalized anxiety disorder
jRCT2031260595Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing SEP-363856 75 mg/day with Placebo (2 arms). Primary endpoint: Change from baseline at Week 8 in Hamilton Anxiety Rating Scale total score. Started Nov 2026; status: recruiting.
02
Drugs
ulotaront
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on jRCT2031260595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260595.